Overview

Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19

Status:
Recruiting

Trial end date:
2021-08-31

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to evaluate the efficacy and safety of XAV-19 drug in patients with moderate-to-severe COVID-19.

Phase:

Phase 2/Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Xenothera SAS

Criteria

Inclusion Criteria:

I1) Male or female patient aged 18 years or over, weighing >50 Kg and <120 Kg, at the time
of signing the informed consent,

I2) Patient presenting in a specialized or an emergency unit

I3) Patient presenting signs of pneumonia evidenced by at least 1 of the following:
auscultation, chest X-Ray, CT scan OR presenting COVID-19 related symptoms having started
less than 10 days prior to screening visit, including at least 2 of the following: fever,
cough, sore throat or nasal discharge, dyspnea (shortness of breath), thoracic pain,
headache or fatigue, myalgia, anosmia, dysgeusia, diarrhea, nausea

I4) Patient with SpO2 > 90% (at ambient air)

I5) Patient with a first positive SARS-CoV-2 test (RT-PCR, RT-qPCR or antigen test) in the
last 10 days or at screening

I6) Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at
screening and use a highly effective birth control until 90 days after the administration
of study drug

I7) Non-vasectomized male patients having a female partner of childbearing potential must
agree to use a highly effective method of contraception until 90 days after the
administration of study drug,

I8) Patient capable of giving signed informed consent.

Exclusion Criteria:

E1) Patient with a positive SARS CoV-2 test (RT-PCR, RT-qPCR or antigen test) of more than
10 days before the screening visit

E2) Patient with multiorgan failure

E3) Patient requiring immediate Intensive Care Unit (ICU) hospitalization

E4) Patient participating in another clinical trial with an investigative agent

E5) Pregnancy or breastfeeding